A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan

por Adam, Ishag, Magzoub, Mamoun, Osman, Maha E, Khalil, Insaf F, Alifrangis, Michael, Elmardi, Khalid A
Publicado 2006

Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

por Khalil, Insaf F, Alifrangis, Michael, Recke, Camilla, Hoegberg, Lotte C, Ronn, Anita, Bygbjerg, Ib C, Koch, Claus
Publicado 2011

The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics

por A-Elbasit, Ishraga E, Alifrangis, Michael, Khalil, Insaf F, Bygbjerg, Ib C, Masuadi, Emad M, Elbashir, Mustafa I, Giha, Hayder A
Publicado 2007

A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria

por Adjei, George O, Goka, Bamenla Q, Enweronu-Laryea, Christabel C, Rodrigues, Onike P, Renner, Lorna, Sulley, Abdul M, Alifrangis, Michael, Khalil, Insaf, Kurtzhals, Jorgen A
Publicado 2014